Literature DB >> 3276619

Biochemical complexity of serum HLA class I molecules.

L M Dobbe1, N J Stam, J J Neefjes, M J Giphart.   

Abstract

Human serum was found to contain a variety of class I-like molecules by Western blotting with anti-class I heavy chain reagents: major bands usually are observed around Mr 44,000, 40,000, and 35,000-37,000. HLA-A24-positive individuals are distinguished by higher serum levels of Mr 44,000 and 40,000 class I-like molecules than those found in HLA-A24-negative individuals. The Mr 44,000 serum molecules are probably intact class I molecules that have been shed from the cell membrane, because they contain both a transmembrane segment (TM), as deduced from detergent-binding experiments, and a cytoplasmic tail (CT), as inferred from reactivity with an antipeptide serum specific for the cytoplasmic domain of class I antigens (RaCT). The Mr 35,000 and 37,000 molecules contain neither a TM nor a CT region and therefore are probably proteolytic breakdown products of cellular and/or serum Mr 44,000 molecules, although the existence of Q10-like molecules in man cannot be ruled out. The Mr 40,000 molecules do not contain a TM region. Mr 40,000 molecules reactive with the RaCT serum were found in the minority (2/13) of sera tested. We conclude that alternative splicing resulting in a precise excision of the TM exon plays a minor role in the generation of serum HLA class I antigens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276619     DOI: 10.1007/bf00346587

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  28 in total

1.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

2.  5' cleavage site in eukaryotic pre-mRNA splicing is determined by the overall 5' splice region, not by the conserved 5' GU.

Authors:  M Aebi; H Hornig; C Weissmann
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

3.  Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-10-11       Impact factor: 49.962

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Soluble HL-A7 antigen: localization in the beta-lipoprotein fraction of human serum.

Authors:  R K Charlton; C M Zmijewski
Journal:  Science       Date:  1970-11-06       Impact factor: 47.728

6.  Analysis of human class I antigens by two-dimensional gel electrophoresis. I. Polymorphism, evidence for additional (non-HLA-A, B, C) gene products, and identification of variant HLA-A, B antigens.

Authors:  R G Vasilov; A Hahn; H Mölders; J J van Rood; M Breuning; H L Ploegh
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

7.  Phase separation of integral membrane proteins in Triton X-114 solution.

Authors:  C Bordier
Journal:  J Biol Chem       Date:  1981-02-25       Impact factor: 5.157

8.  A nonpolymorphic class I gene in the murine major histocompatibility complex.

Authors:  A L Mellor; E H Weiss; M Kress; G Jay; R A Flavell
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

9.  Tissue-specific expression of an unusual H-2 (class I)-related gene.

Authors:  D Cosman; M Kress; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

10.  I-Kk and H-2Kk antigens are shed as supramolecular particles in association with membrane lipids.

Authors:  S G Emerson; R E Cone
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

View more
  27 in total

1.  Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.

Authors:  B Gansuvd; M Hagihara; B Munkhbat; N Kanai; N Morita; N Munkhtuvshin; J Chargui; S Kato; T Hotta; K Tsuji
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

Authors:  F Puppo; F Torre; P Contini; M Ghio; S Brenci; R Brizzolara; N Sinelli; N Campo; F Indiveri; A Picciotto
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

3.  Soluble class I histocompatibility antigens (s-HLA) and beta 2-microglobulin at delivery.

Authors:  A Ferreira; M C García Rodríguez; F Omeñaca; A Jiménez; L M Villar; P Gonzalez-Porqué; G Fontán
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.

Authors:  Giuseppe Murdaca; Paola Contini; Paola Cagnati; Simona Marenco; Giulia Pieri; Francesca Lantieri; Antonino Picciotto; Francesco Puppo
Journal:  Clin Exp Med       Date:  2015-11-14       Impact factor: 3.984

5.  Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay.

Authors:  I Doxiadis; U Westhoff; H Grosse-Wilde
Journal:  Blut       Date:  1989-11

6.  Identification, characterization, and quantitation of soluble HLA antigens in the circulation and peritoneal dialysate of renal patients.

Authors:  F B Gelder; J C McDonald; M D Landreneau; R M McMillan; D F Aultman
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

Review 7.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

8.  HLA-B27 determination using serological methods. A comparison of enzyme immunoassay and a microlymphocytotoxic test with flow cytometry and a molecular biological assay.

Authors:  A Dunky; J Neumüller; C Hübner; G F Fischer; P M Bayer; E Wagner; D W Schwartz; W R Mayr
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

9.  Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?

Authors:  F Puppo; A Picciotto; S Brenci; G Varagona; M Scudeletti; M Ghio; V Balestra; G Celle; F Indiveri
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth.

Authors:  Lorraine R Washburn; Dan Zekzer; Shoshana Eitan; Yuxin Lu; Hoa Dang; Blake Middleton; Christopher J Evans; Jide Tian; Daniel L Kaufman
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.